The aim of our study was to compare infectious complication rates between different prostate biopsy techniques with various number of biopsy cores. In this retrospective study, all patients from 2 hospitals who underwent prostate biopsy between 2012 and 2019 were identified. Cohorts with different types of prostate biopsies were compiled within these hospitals. Primary outcome measure was any registered infectious complication within 7 days post-biopsy. Secondary outcomes were infectious complications within 30 days, hospitalization and bacteremia. To compare the risk of infection following different prostate biopsy techniques, data was fitted into a logistic regression model adjusting for potential confounders. In total, 4,233 prostate biopsies in 3,707 patients were included: TRUSPB 12±1.4 biopsy cores; transperineal magnetic resonance imaging (MRI)-ultrasound fusion guided prostate biopsy 16±3.7 biopsy cores; transrectal targeted MRI-ultrasound fusion guided prostate biopsy 3.1±0.8 biopsy cores; transrectal targeted in-bore MRI guided prostate biopsy 2.8±0.8 biopsy cores.

Date Submitted: 2022-09-23